Icosavax Kicks Off NASDAQ Debut; Trading Almost 150% Higher On IPO Price Of $15

Icosavax Inc ICVX priced an upsized $182 million IPO, which had initially penciled in a $100 million raise.
The new entry on NASDAQ ended up offering just over 12.1 million shares at $15 apiece.
The majority of the funds ($120 million) are going straight to IVX-A12, a combination vaccine candidate targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
Icosavax plans on filing an IND for that program in 1H of 2022.
The Company has initially been working on a vaccine for just RSV, dubbed IVX-121, which is entering a clinical trial in Belgium later in 2021.
Topline data are expected in 1H of 2021.
The Company is also working on two COVID-19 vaccine candidates, IVX-411 and IVX-421. The former entered a Phase 1/2 trial in Australia last month, with proof-of-concept data coming in 1H of 2022.
ICVX shares were trading at $38.20, up 155% from the IPO price of $15 per share.